

DAFTAR PUSTAKA

- Al Aljabeiti, A., Salahuddin, R., Tolar, M. & Tolarova, M. 2017, *Association of TGFβ3 variants with Nonsyndromic Cleft Lip and Palate in Guatemalan Population*. J Den Craniofac Res, 2: 9.
- Ambati, J., Atkinson, J.P. and Gelfand, B. D., 2013, *Immunology of age-related macular degeneration*. Nat. Rev. Immunol. 13: 438–451. doi: 10.1038/nri3459
- Anu, K, Jussi J.P., Janusz, B., Antero, S., Kai, K., 2016, *Inflammation and its role in age-related macular degeneration*, Cell. Mol. Life Sci. 73:1765–1786. <https://doi.org/10.1007/s00018-016-2147-8>.
- Arroba, A.I., Campo, C.A., Aguilar, D.M. and Valverde, A.M, 2018, “IGF-1, inflammation and retinal degeneration. a close network”, *Front. Aging Neurosci.*, 10. 203. <https://doi.org/10.3389/fnagi.2018.00203>.
- Ashraf, M., Souka, A., & Adelman, R. (2016). Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: A review of the literature. Dalam *British Journal of Ophthalmology*(Vol. 100, Nomor 12, hlm. 1596–1604). BMJ Publishing Group. <https://doi.org/10.1136/bjophthalmol-2016-308388>
- Avery, R.L., Castellarin, A.A., Steinle, N.C., Dhoot, D.S., Pieramici, D.J., See, R., Couvillion, S., Nasir, M.A., Rabena, M.D, Maia., M., 2017, *Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab.*, Retina. 37:1847–1858.
- Bobadilla, M., Pariente, A., Oca, A. I., Pelaez, R., Perez-Sala, A., & Larrayoz, I. M. 2022, *Biomarkers as Predictive Factors of Anti-VEGF Response.*, Biomedicine. 1 - 23.
- Bontzos, G., Bagheri, S., Ioanidi, L., Kim, I., Datseris, I., Gragoudas, E., Kabanarou, S., Miller, J., Tsimbaliris, M., 2019, *Non-responders to ranibizumab Anti-VEGF treatment are actually short-term responders: A prospective SD-OCT study*. Ophthalmol Retina. 4(12): 1138–1145. doi:10.1016/j.oret.2019.11.004.
- Browning, D.J., Kaiser P.K., Rosenfeld P.J., Stewart M.W., 2012, *Aflibercept for age-related macular degeneration: a game-changer or quiet addition?*, Am J Ophthalmol. 154(2):222–226.
- Brunnsgaard, H., 2006, *The clinical impact of systemic low-level inflammation in elderly populations. With special reference to cardiovascular disease, dementia and mortality*. Dan Med Bull. 53: 285–309.
- Carlos, E., Luciana, N., Franco, M. R., David, P., Marcio, B., 2013. *VEGF Gene Polymorphism and Response to Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration*: Karger. Ophthalmic Res 2014;51:1–8.
- Chakravarthy, U., Williams, M., 2013, *The AMD Guidelines Group. The royal college of ophthalmologists guidelines on AMD: Executive Summary*. Eye. 27: 1429–1431.

- Chakravarthy, U., Wong, T.Y., Fletcher, A., Piau, E., Evans, C., Zlateva, G., BuAAage, R., Pleil, A. and Mitchell, P., 2010, *Clinical risk factors for age-related macular degeneration: A systematic review and meta-analysis*, BMC Ophthalmology., 10(1). <https://doi.org/10.1186/1471-2415-10-31>.
- Deangelis, M.M., Silveira, A.C., Carr, E.A. and Kim, I.K., 2011, *Genetics of age-related macular degeneration: Current concepts, future directions*, Seminars in Ophthalmology. 26(3), 77–93. <https://doi.org/10.3109/08820538.2011.577129>.
- Dias, J.R., Rodrigues, E.B., Maia, M., 2011, *Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy*, Br J Ophthalmol. 95:1631e1637.
- Fareeha, A., Muhammad, I., Irfan, Z.Q., 2015, *Association of gene polymorphism with serum levels of inflammatory and angiogenic factors in Pakistani patients with age-related macular degeneration*. Molecular Vision. 21:985-999. <http://www.molvis.org/molvis/v21/985>.
- Forouhe, Z.J., Fatemeh, A., Nazanin, M., 2017, *Interleukin-6 participation in pathology of ocular diseases*. 123–131. <http://dx.doi.org/10.1016/j.pathophys.2017.05.005>
- Fritsche, L.G., Chen, W., Schu, M., Yaspan, B.L., Yu, Y., Thorleifsson, G., Zack, D.J., Arakawa, S., Cipriani, V., Ripke, S., Igo, R. P., Buitendijk, G.H.S., Sim, X., Weeks, D.E., Guymer, R.H., Merriam, J E., Francis, P.J., Hannum, G., Agarwal, A., Abecasis, G.R., 2013, *Seven new loci associated with age-related macular degeneration*. Nature Genetics. 45(4): 433–439. <https://doi.org/10.1038/ng.2578>.
- Green, W. R., and Key, S. N., 1977, *Senile macular degeneration: a histopathologic study*, Trans. Am. Ophthalmol., Soc. 75: 180–254. doi: 10.1097/ 00006982-200507001-00005.
- Gurung, R.L., Liesel, M.F., Bennet, J.M., Alex, W.H., Nittin, V, Kathryn, P.B., 2021, *Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal anti-vascular endothelial growth factor injections in clinical practice*. BMJ Open Ophth. 6: e000749. doi:10.1136/bmjophth-2021-000749.
- Han Joo, C., Wootae, Y., Jihyun, Y., Seung, K., Jihyun, L., 2021, *Development of intraretinal fluid in neovascular age-related macular degeneration during anti-vascular endothelial growth factor treatment*. AJOPHT. S0002-9394(21)00394-9.
- Heesterbeek, T.J., 2020, *Risk factors for progression of age-related macular degeneration*. Ophthalmic Physiol Opt. 40(2):140–170.
- Hattenbach, L.O., Falk, B., Nürnberger, F., 2012, *Detection of inducible nitric oxide synthase and vascular endothelial growth factor in choroidal neovascular membranes*. Ophthalmologica. 216:209e214.

- Ida, K.G., Anna, M.K., Pasi, O., 2023, *Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland*. *Annals of medicine*. 55:1. <https://doi.org/10.1080/07853890.2023.2222545>
- Kawasaki. R., Yasuda, M., Song, S.J., 2010, *The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis*. *Ophthalmology*. 117: 921–27.
- Keenan, T.D., Vitale, S., Agron, E., Domalpally, A., Antoszyk, A.N., Elman, M.J., Clemos, T.E., and Chew, E.Y., 2020, *Visual acuity outcomes after anti- VEGF treatment for neovascular age-related macular degeneration: AREDS2 Report Number 19*. *Ophthalmol Retina*. 4(1): 3–12. <https://doi.org/10.1016/j.oret.2019.06.001>.
- Li, J., He, J., Zhang, X., Li, J., and Zhao, P., 2019, *TSP1 ameliorates age-related macular degeneration by regulating the STAT3- iNOS signaling pathway*. *Exp Cell Res*. 388: 111811.
- Lerner, K. L., 2002, *Wild Type*. (Draft Copy) Originally published in: Lerner, KL and Lerner, BW. *World of Genetics*. Thomson| Gale.
- Long, T., Geoffrey, K., Thomas, H, H., Andrew, A, C., 2021, *Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives*. *Clinical Ophthalmology* 15: 3351–3367.
- Madyono, B., Sastroasmoro, S., Budiman, I., and Purwanto, S., 2014, *Perkiraan besar sampel*, In S. Sastroasmoro & S. Ismael (Eds.). *Dasar-dasar Metodologi Peneilitian Klinis.*, (5th ed., pp. 352–396). Sagung Seto.
- M.D., G.L., S., M.D., L.B., C.M.d, and G.A.C., 2013, *Aao, basic and clinical science course: retina and vitreous, section 12*. (American Academy of Ophthalmology,).
- Madhukar, S., Agrawal, Neena, S., 2012, *Interleukin-6 (IL-6)-597 A/G (rs1800797) & -174 G/C (rs1800795) gene polymorphisms in type 2 diabetes*. *Indian J Med*.
- Mehta, S., 2015, *Age-Related Macular Degeneration*. *Prim Care Clin Office Pract* 42: 377–391.
- Miriam, B., Ana, P.I.O., Ana, Rafael, P.P.S., Alvaroz, L.M., Ignacio., 2022, *Biomarkers as Predictive factors of anti-vegf response*. *Biomedicines*. 10, 1003. <https://doi.org/10.3390/biomedicines10051003>.
- Muhammad, R.C., Joanna, D.C, James, T., 2021, *Ten-year real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration*. *Clinical Ophthalmology*.15: 279–287
- Narayanan, R., Butani, V., Boyer, D.S., 2007, *Complement factor H polymorphism in age-related macular degeneration*. *Ophthalmology*. 114:1327–1331.
- Nasim, S., Mohammad, R.E., Paula, S.F, Kevin, S., Cristina, M.K., 2019, *Age-related macular degeneration (amd): a review on its epidemiology and risk factors*. *The Open Ophthalmology Journal*. 13: 90-99. <https://doi.org/10.2174/1874364101913010090>.

- Nawash, B., Ong, J., Driban, M., Hwang, J., Chen, J., Selvam, A., Chhablani, J., 2023, *Prognostic Optical Coherence Tomography Biomarkers in Neovascular Age-Related Macular Degeneration*. J. Clin. Med. 1 -16.
- Phadikar, P., Saxena, B., Ruia, R., Lai, T, Y, Y., Meyer, C., and Elliott, D., 2017, *The Key Potential Of Spectral Domain Optical Coherence Tomography Imaging Based Retinal Biomarkers,*” International Journal of Retina and Vitreous. vol. 3, no. 1, pp. 1–10.
- Pascolini, D., and Mariotti, S.P., 2012, *Global estimates of visual impairment: 2010*. Br. J. Ophthalmol. 96: 614–618.
- Pauliekhoff, D., Kirchhof, B., 2011, *Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of “lesion activity”*. Graefes Arch Clin Exp Ophthalmol. 249: 631–632.
- Reiter, G, S., Grechenig, C., Vogl, W, D., 2021, *Analysis of fluid volume and its impact on visual acuity in the fluid study as quantified with deep learning*. Retina. 41(6):1318-1328.
- Regillo, C.D., Busbee, B.G., Ho, A.C., Ding, B., Haskova, Z., 2015, *Baseline predictors of 12-month treatment response to ranibizumab in patients with wet age-related macular degeneration*. Am J Ophthalmol. 160(5):1014–1023.e1012. doi:10.1016/j.ajo.2015.07.034
- Ross, R. J., Verma, V., Rosenberg, K.I., Chan, C.C., and Tuo, J., 2007, *Genetic markers and biomarkers for age-related macular degeneration*. 2(3): 443–457.
- Sadda, S, R., Tuomi, T., Ding, B., Fung, B, A., and Hopkins, J., 2018, *Macular atrophy in the HARBOR study for 12 Journal of Ophthalmology neovascular age-related macular degeneration*. Ophthalmology, vol. 125, no. 6, pp. 878–886.
- Scholz, R., Caramoy, A., Bhuckory, M.B., Rashid, K., Chen, M., Xu, H., 2015, *Targeting translocator protein (18 kDa) (TSPO) dampens proinflammatory microglia reactivity in the retina and protects from degeneration*. J. Neuroinflamm. 12:201. <https://doi.org/10.1186/s12974-015-0422-5>.
- Seddon, J.M., Gensler, G., Milton, R.C., 2004, *Association between C-reactive protein and age-related macular degeneration*. JAMA. 291:704–710.
- Solomon, S.D., Lindsley, K., Vedula, S.S., Krzystolik, M.G., and Hawkins, B.S., 2019, *Anti-vascular endothelial growth factor for neovascular age-related macular degeneration*. Cochrane Database Syst. Rev. 8, CD005139.
- Song, P., Du, Y., Chan, K.Y., Theodoratou, E., Rudan, I., 2017, *The national and subnational prevalence and burden of age-related macular degeneration in China*. J Glob Health. 7(2):020703.
- Tong, Y., Liao, J., Zhang, Y., Zhou, J., Zhang, H., Mao, M., 2010, *LOC387715/HTRA1 gene Polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis*, Mol Vis., 16:1958-81. [PMID: 21031019].

- Wei, T., Jingling, Zou., Shigeo, Y., Bing, J., Yedi, Z., 2020, *The role of inflammation in age-related macular degeneration*. Int. J. Biol. Sci. 16(15): 2989-3001. <https://doi.org/10.7150/ijbs.49890>.
- Wong, W.L., Su, X., Li, X., 2014, *Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis*, Lancet Glob Health., 2(2):106-116.
- Zaimah, Z.T., Nurfida, K.A., Sanny. S., 2021, *The Polymorphism in Interleukin-6-597 G/A Gene and their Levels on Type 2 Diabetic Patients*. Med Sci. 2021 Jan 25; 9(A):57-60.
- Zarbin, M.A., 2004, *Current concepts in the pathogenesis of age-related macular degeneration*. Archives of Ophthalmology. 122(4): 598–614. <https://doi.org/10.1001/archophth.122.4.598>.
- Zhou, J., Pham, L., Zhang, N., He, S., Gamulescu M.A., Spee, C., Ryan, S.J., Hinton, D.R., 2005, *Neutrophils promote experimental choroidal neovascularization*. Mol Vis. 11:414-24. [PMID: 15988410].
- Zuhal, Y., Nil, I.U., Filiz, Y., Aylin, S.D., 2012, *Choroidal neovascular membrane in age-related macular degeneration is associated with increased interleukin-6*. International Journal of Gerontology 6. 101-104. doi: 10.1016/j.ijge.2012.01.018.